TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38996201

Group type: EXPERIMENTAL
Intervention: Neoadjuvant Docetaxel, Oxaliplatin, and S-1 plus surgery and adjuvant S-1
Number of subjects: 0
Study: 38996333

Group type: EXPERIMENTAL
Intervention: Complex Interactive Multimodal Intervention (CIMI)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control group (self-guided intervention)
Number of subjects: 245
Study: 38996463

Group type: EXPERIMENTAL
Intervention: CAR22 at 1 million CAR T cells per kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CAR22 at 3 million CAR T cells per kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Maximum tolerated dose of CAR22
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall CAR T-cell product manufacturing
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall patient outcomes
Number of subjects: 40
Study: 38996519

Group type: EXPERIMENTAL
Intervention: FU/FA + Pmab
Number of subjects: 387

Group type: COMPARATOR
Intervention: FU/FA
Number of subjects: 387
Study: 38996972

Group type: EXPERIMENTAL
Intervention: 1HP (daily rifapentine plus isoniazid for 28 days)
Number of subjects: 490

Group type: COMPARATOR
Intervention: 3HP (weekly rifapentine plus isoniazid for 3 months)
Number of subjects: 490
Study: 38997091

Group type: EXPERIMENTAL
Intervention: Home induction with a transcervical Foley catheter
Number of subjects: 45

Group type: COMPARATOR
Intervention: Expectant management (control group)
Number of subjects: 45
Study: 38997229

Group type: EXPERIMENTAL
Intervention: Dolutegravir-based regimen (135 participants)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Efavirenz-based regimen (133 participants)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Clay-based Traditional Medicine (TM) use (34% of participants)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Mumbwa (clay-based TM) coadministration
Number of subjects: 268
Study: 38997279

Group type: COMPARATOR
Intervention: Gut microbiota-based machine learning (ML) algorithms for ALD diagnosis
Number of subjects: 263

Group type: COMPARATOR
Intervention: Gut microbiota-based machine learning (ML) algorithms for MASLD diagnosis
Number of subjects: 263

Group type: COMPARATOR
Intervention: Gut microbiota-based machine learning (ML) algorithms for ALD and MASLD external validation
Number of subjects: 263
Study: 38997435

Group type: EXPERIMENTAL
Intervention: Total testosterone
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: SHBG
Number of subjects: 907
Study: 38997439

Group type: EXPERIMENTAL
Intervention: SOPeD web-based foot-ankle therapeutic exercise program
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care for diabetic foot
Number of subjects: 62
Study: 38997441

Group type: EXPERIMENTAL
Intervention: Online Pilates Group (OPG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 0
Study: 38997607

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) therapy
Number of subjects: 12
Study: 38997620

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily for 12 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 38997647

Group type: EXPERIMENTAL
Intervention: Unstable surfaces (UNST)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Stable surfaces (ST)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Maximal isometric quadriceps strength (UNST)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Maximal isometric quadriceps strength (ST)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 38997668

Group type: EXPERIMENTAL
Intervention: Bilateral blood pressure measurement
Number of subjects: 4517
Study: 38997676

Group type: EXPERIMENTAL
Intervention: Azithromycin (48 weeks duration)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study: 38997684

Group type: EXPERIMENTAL
Intervention: Personalized visualized oral health education combined with conventional oral hygiene education
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional oral hygiene education only
Number of subjects: 56
Study: 38997778

Group type: EXPERIMENTAL
Intervention: Tailored cardiac rehabilitation program (12-week center-based program including supervised exercise training and patient education workshops)
Number of subjects: 8
Study: 38999331

Group type: EXPERIMENTAL
Intervention: Centhaquine
Number of subjects: 0
Study: 39001374

Group type: EXPERIMENTAL
Intervention: Alpha DaRT treatment
Number of subjects: 71
Study: 39001413

Group type: EXPERIMENTAL
Intervention: Prospective observational cohort study
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Clinical and biological samples collection
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PRO) data collection
Number of subjects: 102
Study: 39001621

Group type: EXPERIMENTAL
Intervention: Bismuth-metronidazole-tetracycline and clarithromycin-amoxicillin-bismuth quadruple therapies
Number of subjects: 53636

Group type: EXPERIMENTAL
Intervention: Concomitant clarithromycin-amoxicillin-tinidazole/metronidazole
Number of subjects: 53636

Group type: EXPERIMENTAL
Intervention: Sequential clarithromycin-amoxicillin-tinidazole/metronidazole
Number of subjects: 53636

Group type: COMPARATOR
Intervention: Dyspepsia with normal endoscopy
Number of subjects: 53636

Group type: COMPARATOR
Intervention: Duodenal ulcer
Number of subjects: 53636

Group type: EXPERIMENTAL
Intervention: Duodenal ulcer and preneoplastic lesions
Number of subjects: 53636

Group type: EXPERIMENTAL
Intervention: Overall treatment effectiveness by indication
Number of subjects: 53636
Study: 39001736

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging (MRI)
Number of subjects: 80
Study: 39001864

Group type: EXPERIMENTAL
Intervention: Jewel patch wearable cardioverter-defibrillator (P-WCD) delivering a single shock of 150 J
Number of subjects: 18
Study: 39001910

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (AC)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) in patients ≤50 years
Number of subjects: 282

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (AC) in patients ≤50 years
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) in patients >50 years
Number of subjects: 282

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (AC) in patients >50 years
Number of subjects: 282
Study: 39001922

Group type: EXPERIMENTAL
Intervention: mXACT Total Prosthesis Offcenter
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: mXACT Total Prosthesis Center, mXACT Total Prosthesis Offcenter, mXACT PRO Total Prosthesis
Number of subjects: 103
Study: 39002005

Group type: EXPERIMENTAL
Intervention: Conditional economic incentives based on PrEP adherence grading system ($20 for high adherence, $10 for medium adherence, $0 for low adherence)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Conditional economic incentives
Number of subjects: 110
Study: 39002092

Group type: EXPERIMENTAL
Intervention: Lebrikizumab Q2W
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Lebrikizumab Q4W
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 39002122

Group type: EXPERIMENTAL
Intervention: TCK-276 25 mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: TCK-276 75 mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: TCK-276 175 mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 39002328

Group type: EXPERIMENTAL
Intervention: Educational program (4 group sessions and 6 follow-up phone calls)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 197
Study: 39002346

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-NHL-HG29 questionnaire for high-grade NHL
Number of subjects: 3922

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-NHL-LG20 questionnaire for low-grade NHL
Number of subjects: 3922

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-HL27 questionnaire for Hodgkin lymphoma
Number of subjects: 3922

Group type: EXPERIMENTAL
Intervention: Multivariable regression analyses for DLBCL, follicular and HL
Number of subjects: 3922
Study: 39002347

Group type: EXPERIMENTAL
Intervention: FOLFIRI
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: CAPTEM
Number of subjects: 53
Study: 39002409

Group type: EXPERIMENTAL
Intervention: Pushing technique with saline
Number of subjects: 60
Study: 39002551

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (10 mg twice daily for ages 12-18, 5 mg twice daily for ages 6-12, 4 mg/m² for ages 2-6)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 45
Study: 39002624

Group type: EXPERIMENTAL
Intervention: Diet (caloric intake)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Exercise habits
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Substance use (alcohol, tobacco, marijuana)
Number of subjects: 115
Study: 39002625

Group type: EXPERIMENTAL
Intervention: Pharmacy sourced medical abortion (mifepristone and misoprostol)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Clinic sourced medical abortion (mifepristone and misoprostol)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 2000
Study: 39002641

Group type: EXPERIMENTAL
Intervention: Pemvidutide treatment
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 39002945

Group type: EXPERIMENTAL
Intervention: Rivaroxaban with aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivaroxaban alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study: 39003135

Group type: EXPERIMENTAL
Intervention: Cumulative burden and increasing trends of body mass index (BMI) originating in childhood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early weight management
Number of subjects: 0
Study: 39003182

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil administered concomitantly to radiotherapy
Number of subjects: 10
Study: 39003185

Group type: EXPERIMENTAL
Intervention: Neoadjuvant durvalumab plus platinum-based chemotherapy (D+CT) followed by adjuvant durvalumab
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Consolidation durvalumab after chemoradiotherapy
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Neoadjuvant D+CT followed by surgery or chemoradiotherapy
Number of subjects: 140
Study: 39003225

Group type: EXPERIMENTAL
Intervention: Exclusive lipomodeling reconstruction after mastectomy (Group 1)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Lipomodeling reconstruction in addition to a flap (Group 2)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Exclusive lipomodeling reconstruction after tumorectomy (Group 3)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Postoperative complications across all groups
Number of subjects: 91
Study: 39003306

Group type: EXPERIMENTAL
Intervention: gBRCA1/2 mutations
Number of subjects: 471

Group type: COMPARATOR
Intervention: Non-gBRCA1/2 mutation carriers
Number of subjects: 471

Group type: COMPARATOR
Intervention: Other cancer risk gene mutations
Number of subjects: 471

Group type: COMPARATOR
Intervention: Somatic mutations (e.g., TP53, CDH1, PTEN)
Number of subjects: 471
Study: 39003347

Group type: EXPERIMENTAL
Intervention: Mycoprotein (MYC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 24
Study: 39003423

Group type: EXPERIMENTAL
Intervention: Echocardiographic diagnostic algorithm for systematic classification of interatrial communications
Number of subjects: 12385
Study: 39003483

Group type: EXPERIMENTAL
Intervention: Early hysteroscopy (2 times: early and late) in group A
Number of subjects: 66

Group type: COMPARATOR
Intervention: Late hystroscopy (6 months post suction D&C) in group B
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 66
Study: 39003487

Group type: EXPERIMENTAL
Intervention: Mid-regional pro-atrial natriuretic peptide (MRproANP)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Midregional pro-adrenomedullin (MRproADM)
Number of subjects: 418
Study: 39003753

Group type: EXPERIMENTAL
Intervention: Dual-task Timed Up-and-Go test (cognitive) (DTUG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-m walk backward test (3MBWT)
Number of subjects: 0
Study: 39003935

Group type: EXPERIMENTAL
Intervention: NLP
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: PMRE
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control
Number of subjects: 99
Study: 39003957

Group type: EXPERIMENTAL
Intervention: Calorie Restriction (CR)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intermittent Fasting (IF)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ad Libitum Habitual Diet (AL)
Number of subjects: 44
Study: 39004096

Group type: EXPERIMENTAL
Intervention: H3N2 M2SR vaccine plus Fluzone HD (n=94)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: H3N2 M2SR vaccine plus placebo (n=89)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Fluzone HD plus placebo (n=92)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo alone (n=30)
Number of subjects: 305
Study: 39004211

Group type: EXPERIMENTAL
Intervention: Fasinumab clinical trials (not specified dosage or duration)
Number of subjects: 21997

Group type: COMPARATOR
Intervention: X-ray imaging
Number of subjects: 21997

Group type: COMPARATOR
Intervention: MRI imaging
Number of subjects: 21997
Study: 39004217

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion for 48 hours to maintain HR at 60 to 90 beats/min
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 90
Study: 39004223

Group type: EXPERIMENTAL
Intervention: Low-Glycemic Index Mediterranean-Style Eating Pattern (MED-HEP)
Number of subjects: 160

Group type: COMPARATOR
Intervention: High-Glycemic Index Mediterranean-Style Eating Pattern (MED-HEP)
Number of subjects: 160
Study: 39004283

Group type: EXPERIMENTAL
Intervention: Specialized nutritious food (SNF) and social and behavior change communication (SBCC) intervention
Number of subjects: 2928

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2928
Study: 39004298

Group type: EXPERIMENTAL
Intervention: Independent online training (IND)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Maintenance of Certification-4 (MOC) activity
Number of subjects: 210
Study: 39004432

Group type: EXPERIMENTAL
Intervention: ixekizumab (IXE) 80 mg every 4 weeks
Number of subjects: 81
Study: 39004434

Group type: EXPERIMENTAL
Intervention: BCG-Denmark vaccine (0.05 mL intradermal dose)
Number of subjects: 1272

Group type: COMPARATOR
Intervention: No BCG vaccination
Number of subjects: 1272
Study: 39004647

Group type: EXPERIMENTAL
Intervention: SHR-A1811 at 4.8 mg/kg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: SHR-A1811 at 8.0 mg/kg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: SHR-A1811
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: SHR-A1811 at 6.4 mg/kg
Number of subjects: 63
Study: 39004848

Group type: EXPERIMENTAL
Intervention: Physical restraint
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Anti-psychotic medications
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Dialysis
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Chronic drug abuse
Number of subjects: 647
Study: 39005691

Group type: EXPERIMENTAL
Intervention: Debulking therapy (including rituximab-containing immunochemotherapy regimens and radiotherapy)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Axi-cel treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Debulking chemotherapy
Number of subjects: 50
Study: 39006159

Group type: EXPERIMENTAL
Intervention: PRO-based follow-up
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 152
Study: 39006315

Group type: EXPERIMENTAL
Intervention: RBL (REBYOTA®) administration after non-CDI antibiotic use
Number of subjects: 43

Group type: COMPARATOR
Intervention: High-risk antibiotics
Number of subjects: 43
Study: 39006430

Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% eyedrops twice daily for four weeks
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Placebo twice daily for four weeks
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% eyedrops
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study: 39006439

Group type: EXPERIMENTAL
Intervention: Epcoritamab-containing regimens
Number of subjects: 0
Study: 39007062

Group type: EXPERIMENTAL
Intervention: Mogamulizumab treatment
Number of subjects: 339

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 339
Study: 39007065

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) at a dose of 30 mg/m² combined with cyclophosphamide and vincristine (VPC)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) at a dose of 30 mg/m²
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: VPC regimen
Number of subjects: 34
Study: 39007063

Group type: EXPERIMENTAL
Intervention: Tuberculosis treatment decision algorithms (TDAs)
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: One-step diagnostic model
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Two-step diagnostic model
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Tuberculosis prevalence
Number of subjects: 603
Study: 39007066

Group type: EXPERIMENTAL
Intervention: MIL62 combined with lenalidomide
Number of subjects: 54
Study: 39007552

Group type: EXPERIMENTAL
Intervention: TCAR with MicroNET-covered neuroprotective stent (CGuard)
Number of subjects: 106
Study: 39007556

Group type: EXPERIMENTAL
Intervention: Emergency mechanical reperfusion (EMR) treatment
Number of subjects: 101

Group type: COMPARATOR
Intervention: EMR-untreated patients
Number of subjects: 101
Study: 39007703

Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy combined with Cognitive-Behavioral Therapy for eating disorders (TF-CBT-WB)
Number of subjects: 30
Study: 39007830

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual antithrombotic therapy (DAT; OAC plus P2Y12 inhibitor)
Number of subjects: 0
Study: 39007836

Group type: EXPERIMENTAL
Intervention: Serum vitamin D levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemoglobin A1c levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin B12 levels
Number of subjects: 0
Study: 39007915

Group type: EXPERIMENTAL
Intervention: KLF10 deletion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KLF10 binding to atrophy genes
Number of subjects: 0
Study: 39007942

Group type: EXPERIMENTAL
Intervention: Paromomycin plus miltefosine (Arm 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B plus miltefosine (Arm 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low IFN-γ, TNF and IL-1β before treatment (Arm 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arm 1 treatment in patients with low IFN-γ production at D0
Number of subjects: 0
Study: 39007997

Group type: EXPERIMENTAL
Intervention: 3 mg/kg caffeine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 6 mg/kg caffeine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 39008026

Group type: EXPERIMENTAL
Intervention: LD EC-ASA
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: LD PL-ASA
Number of subjects: 47

Group type: COMPARATOR
Intervention: Bayer
Number of subjects: 47
Study: 39008067

Group type: EXPERIMENTAL
Intervention: Rechallenge of RLT (Radioligand Therapy)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Rechallenge of RLT
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Second and third rechallenge series of RLT
Number of subjects: 47
Study: 39008191

Group type: EXPERIMENTAL
Intervention: Single-item sleep disturbance numerical rating scale (SD NRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-item Subject Sleep Diary (SSD)
Number of subjects: 0
Study: 39008208

Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX (Arm 1)
Number of subjects: 126

Group type: COMPARATOR
Intervention: mFOLFIRINOX and hypofractionated radiotherapy (Arm 2)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 126
Study: 39008236

Group type: EXPERIMENTAL
Intervention: Tirzepatide (pooled doses of 5, 10, and 15 mg)
Number of subjects: 1428

Group type: COMPARATOR
Intervention: Insulin Lispro
Number of subjects: 1428
Study: 39008317

Group type: EXPERIMENTAL
Intervention: STOMP intervention (Skills to Manage Pain)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 278
Study: 39008350

Group type: EXPERIMENTAL
Intervention: Real-world physical behavior measures derived from wearable accelerometers
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Submaximal exercise test estimating aerobic fitness (predicted submaximal oxygen uptake)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Self-reported well-being and physical function assessments
Number of subjects: 86
Study: 39008481

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg) and WT1/DC vaccination (8-10 x 106 cells/vaccination) in combination with standard-of-care chemotherapy (cisplatinum 75mg/m2 and pemetrexed 500mg/m2)
Number of subjects: 15
Study: 39008542

Group type: EXPERIMENTAL
Intervention: Cladribine (CLAD) tablets
Number of subjects: 240
Study: 39008826

Group type: EXPERIMENTAL
Intervention: Luteal estradiol (E2) pretreatment
Number of subjects: 324
Study: 39008858

Group type: EXPERIMENTAL
Intervention: Breast cancer screening decision aid (DA) intervention
Number of subjects: 495
Study: 39008947

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 39008999

Group type: EXPERIMENTAL
Intervention: Emtricitabine plus tenofovir alafenamide (200/300 mg)
Number of subjects: 5399

Group type: COMPARATOR
Intervention: Emtricitabine plus tenofovir disoproxil fumarate (200/25 mg)
Number of subjects: 5399
Study: 39009040

Group type: EXPERIMENTAL
Intervention: R-BAC + DA (dornase alfa)
Number of subjects: 39

Group type: COMPARATOR
Intervention: R-BAC (control group)
Number of subjects: 39
Study: 39009085

Group type: EXPERIMENTAL
Intervention: Bulevirtide 2 mg/day
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Bulevirtide 10 mg/day
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 150